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Abstract
Background: Over the years, reports implicate improper anti-malarial use as a major contributor of morbidity and
mortality amongst millions of residents in malaria endemic areas, Kenya included. However, there are limited
reports on improper use of Artemisinin-based Combination Therapy (ACT) which is a first-line drug in the treatment
of malaria in Kenya. Knowing this is important for ensured sustainable cure rates and also protection against the
emergence of resistant malarial parasites. We therefore investigated ACT adherence level, factors associated with
non-adherence and accessibility in households (n = 297) in rural location of Southeast Alego location in Siaya
County in western Kenya.
Methods: ACT Adherence level was assessed with reference to the duration of treatment and number of tablets
taken. Using systematic random sampling technique, a questionnaire was administered to a particular household
member who had the most recent malaria episode (<2 weeks) and used ACT for cure. Parents/caretakers provided
information for children aged <13 years. Key Informant Interviews (KIIs) were also conducted with healthcare
providers and private dispensing chemist operators.
Results: Adherence to ACT prescription remained low at 42.1% and 57.9% among individuals above 13 and less
than 13 years, respectively. Stratification by demographic and socio-economic characteristics in relation to ACT
adherence revealed that age (P= 0.011), education level (P< 0.01), ability to read (P< 0.01) and household (HH)
monthly income (P= 0.002) significantly affected the level of ACT adherence. Consistently, logistic regression model
demonstrated that low age (OR, 0.571, 95% CI, 0.360-0.905; P= 0.017), higher education level (OR, 0.074; 95% CI
0.017-0.322; P< 0.01), ability to read (OR, 0.285, 95% CI, 0.167-0.486; P< 0.01) and higher income (Ksh.> 9000; OR,
0.340; 95% CI, 0.167-0.694; P= 0.003) were associated with ACT adherence. In addition, about 52.9% of the
respondents reported that ACT was not always available at the source and that drug availability (P = 0.020) and
distance to drug source (P< 0.01) significantly affected accessibility.
Conclusions: This study demonstrates that more than half of those who get ACT prescription do not take
recommended dose and that accessibility is of concern. The findings of this study suggest a potential need to
improve accessibility and also initiate programmatic interventions to encourage patient-centred care.
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Background
Malaria is still a major cause of morbidity and mortality
worldwide [1] especially in developing countries such as
sub-Saharan Africa. It is estimated that about 40% of the
world’s population live in malariouos areas [2] with most
of the malaria-related morbidity and mortality resulting
from Plasmodium falciparum infection [3]. Furthermore,
it has been demonstrated that about 90% of the mortal-
ities occur in sub-Saharan Africa, with 85% of these
malaria-related mortalities occurring in children below
five years of age and in pregnant women [3]. In Kenya,
malaria is estimated to affect over 11 million people each
year, majority of which, are from P. falciparum holoen-
demic transmission areas [4] with about 20-45 % of hos-
pital admissions and 25-35 % of outpatient clinic visits
due to malaria infection [2].
Despite the enormous health burden placed on mil-
lions of lives each year in sub-Saharan Africa, there has
been a lot of concern regarding the usage of anti-malarial
drugs [5]. Prompt and effective treatment has been key
in combating malaria and prevention of disease [6]. Pre-
vious studies reported that prescribing health care physi-
cians and the patients, particularly those that rely on the
government supplies, continually battle with ‘a drug is
out of stock’ syndrome and these challenges lead to non-
adherence to effective anti-malarial drugs [7]. Another
challenge for effective intervention is non-adherence due
to socio-economic, cultural, environmental factors and in-
dividual differences [8]. Non-adherence to these drugs
may promote resistance by the malarial parasites to the
available drugs. For example, chloroquine, a drug that was
once highly effective against the parasites that cause the
disease, has become compromised as drug-resistant P. fal-
ciparum parasites have become increasingly prevalent in
the recent decades [9]. This was followed by resistance to
other drugs, including sulfadoxine-pyrimethamine (SP),
mefloquine, and quinine [10]. Globally, anti-malarial drug
resistance undermines efforts to reduce the public health
burden in areas where malaria transmission occurs [10].
Artemisinin-based Combination Therapy (ACT) is one
strategy recommended to increase cure rates in malaria
and to contain resistance by P. falciparum worldwide
[2]. ACT has been recommended as a first-line drug in
treatment of malaria in Kenya since 2004 [11]. At the
time of its introduction, there was no proper guideline
on ACT use [12] and the drug soon became a routine
medication given to patients presenting at the health fa-
cilities with clinical symptoms of malaria [12]. The drug
was and is currently being prescribed without laboratory
confirmation for malaria, particularly in remote areas
where most health facilities do not have laboratory ser-
vices [12]. Among the questions surrounding this treat-
ment prescription is the extent to which patients
complete the recommended doses. With such improper
usage, there is likely to be resistance to ACT by parasites
in populations resident in P. falciparum holoendemic re-
gion such as in western Kenya. As such, it is critical to
establish the extent of drug adherence and accessibility,
particularly in the remote and resource-constrained
areas such as in western Kenya [13].
In 1994, the Government of Kenya implemented the
National Drug Policy to check on medication, prescrip-
tion and promotion of rational drug use [14]. As such,
any drug that was brought into the Kenyan market had
to be guided by this policy. However, it is not clear if this
policy has an impact on the effective treatment of ACT
[12]. The current study site, a remote location within
Siaya County, is situated in a P. falciparum holoendemic
transmission area of western Kenya. Malaria transmis-
sion occurs all year round, peaking in the rainy season
months of April and May [15]. The patterns of use of
anti-malarials include self-prescription, sharing of drugs
with friends and relatives and premature discontinuation
of treatment course [16]. Due to high endemicity, the
households living in these regions have adopted mechan-
isms for surviving constant malarial episodes rather than
seek adequate healthcare. In order to inform effective
treatment intervention, it is imperative to assess the ad-
herence levels, causes of non-adherence and accessibility
to ACT in this population resident in this holoendemic
region of Siaya County in western Kenya.
Methods
Study setting
The current study was carried out in Southeast Alego lo-
cation in Karemo division of Siaya County, Nyanza Prov-
ince, Kenya. In 2009, the national housing and population
census, recorded that Karemo division had a total popula-
tion of 84,986 with an urban population of 19,611. The
total area of the division is 235.1 km2 with a population
density of approximately 350 people/km2 [17]. Karemo
division has five locations; Siaya township, North Alego,
East Alego, South Alego and Southeast Alego locations.
Southeast Alego location consists of four sub-locations;
Masumbi, Nyang’oma Kogelo, Mur-Ng’iya and Bar-Agulu
sub-locations. The area experiences two rainy seasons; the
long rainy season (between April-June) and the short rainy
season (between October-December). Challenges faced by
the community include low farm productivity, high rates
of unemployment, and most importantly, resource-
constrained health facilities due to poverty. These act as
the primary drawbacks in the control of infectious disease
such as malaria, with the highest rates of infections being
experienced immediately after the rainy seasons [17].
Study participants
In order to determine adherence level, and causes of
non-adherence and accessibility of ACT in the study
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population at a point in time, residents living within
households (n = 297) in the above described remote re-
gion of Siaya County in western Kenya, were recruited.
This was a cross-sectional survey in which sampling
was carried out using multi-stage and probability pro-
portion to size sampling methods. Under these method-
ologies, rather than using all the elements contained in
the selected clusters, the researcher randomly selected
elements from each cluster. Constructing the clusters
was the first stage while deciding what elements within
the cluster to use was the second stage. The divisions,
locations, sub-locations and the villages formed the
clusters. Siaya District has three divisions namely Kar-
emo, Boro and Uranga divisions (according to the ad-
ministrative boundaries at the time of the study)
(Figure 1). Karemo division has five locations namely;
Siaya Township, North Alego, East Alego, South Alego
and Southeast Alego was selected as study units at the
division level. Southeast Alego location, which has four
sub-locations namely Masumbi, Nyang’oma Kogelo,
Mur Ngiya and Bar Agulu was selected at the location
level. The sample size was drawn from all the four sub-
locations of Southeast Alego location. The sub-locations
had a total of forty two (42) villages. To ensure equal
representation from each of the sub-locations and the
villages, data on the number households in all the sub-
locations and villages were obtained from Kenya Bureau
of Statistics offices in Siaya District. The obtained data
was then used in determining the proportionate sample
size for each sub-location and village. This site was tar-
geted for the study since it is one of the areas with
highest malaria burden in the district. In addition, inter-
ventions such as stable supply of ACT were being
implemented in this study area at the time of the study
(Figure 1). These methodologies were applied since a
complete list of all members of the population did not
exist. This strategy was preceded by systematic random
sampling in 388 households (in which a member had
used an anti-malarial two weeks prior to the interview).
The sample size was based on Fisher’s formula for sam-
ple size estimation [18] taking into account population
size greater than 10, 000 (i.e. a total of 17,780 people
were resident in the study area at the time of the study).
The formula for sample size determination used the
prevalence of non-adherence to anti-malarial and this
was estimated at 50% since the prevalence is not
known.
Sampling design
Multi-stage and probability proportion to size methods
were used to determine the sample size per sub-location
in the study area. Systematic random sampling method
was then used to sample out the households to be
recruited as sampling unit [19,20]. Under this method-
ology, a member with a recent malaria episode from
every third household on entering a village was recruited
and interviewed. In the absence of a recent malaria case
(within two weeks prior to the survey), the interviewer
moved to the next household. From the 388 sampled
households, a total of 297 who were either laboratory-
diagnosed or had self-reported episodes, used ACT in
treating malaria. The others (91) used other anti-
malarial drugs which were not artemisinin-based. In the
absence of laboratory diagnosis, malaria according to
residents in the study area was defined by either the
presence of/or mixed symptoms of fever, diarrhoea,
vomiting and joint pains. However, if more than one in-
dividual in a household had experienced malaria and
had used anti-malarial within the described period (i.e.
two weeks), then focus was on the most current episode,
while the rest were excluded. This strategy was adopted
so as to capture the most recent pattern of anti-malarial
drug use and to minimize errors associated with recall.
In children <13 years, the parents/caregivers or a legal
guardian were interviewed. Data was collected through





North Siaya Southeast South East Alego
Sub-locations Masumbi Bar Agulu
Villages (sample size) 11villages 9 villages (86) 10 villages 11 villages 
Figure 1 The figure presents the different levels of clustering in the sampling frame. Proportionate analysis was used to determine the
sample size for each of the sub-locations.
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households. Information on the anti-malarial drugs
taken, adherence and causes of non-adherence to ACT
and accessibility to the drug were collected. Adherence
level to ACT was then assessed by duration of treatment
and number of tablets taken in relation to the age of the
patient.
Key Informant Interviews (KIIs) were also conducted
with Kenyan regulatory body-approved healthcare provi-
ders and dispensing chemist operators in the study area.
This included 3 health care providers [1 at Ng’iya Health
Centre (HC), 1 at Nyang’oma Kogelo Dispensary and 1 at
Bar-Agulu Dispensary) and with 3 pharmacists (1 at
Ng’iya shopping center (SC), 1 at Nyang’oma Kogelo SC
and 1 at Bar-Agulu SC). Saturated sampling design was
used to arrive at the number of the key informants.
Through the KIIs, information on adherence to prescribed
drugs, reasons for non-adherence and accessibility of
ACT was collected. The study was approved by the ethical
and scientific review committees at the Maseno Univer-
sity, Kenya and the Kenya National Council for Science
and Technology Board.
Research procedure
Quantitative data was collected from 388 households
[from which those using ACT (n = 297) was obtained].
The interview was carried out using structured pre-
tested questionnaire, administered to the particular fam-
ily member who had malaria and used the anti-malarial
drugs in the household. However, in children below
<13 years, parents/caretakers or a legal guardian pro-
vided the information. Using multi-stage and systematic
random sampling, households with recent malaria epi-
sodes (two weeks prior to interview date) were estab-
lished. In each sub-location in the study area, a sample
proportion to the total household size was sampled and
interviewed. Particular emphasis was on the most recent
episode of self/presumptive or laboratory diagnosed mal-
aria in the household within the last two weeks.
Prior to the actual study, field assistants’/enumerators
(n = 4) who are residents of Southeast Alego location
and with a minimum of fourth form level of formal edu-
cation were interviewed and recruited. The enumerators
were fluent in English, Swahili and Luo languages.
Training of the research assistants on survey interview-
ing techniques was performed for one day, followed by
another day of pre-testing of survey tools and method-
ologies in Pap Nyadiel village, Masumbi sub-location (a
neighboring region exhibiting the same characteristics as
the study site). This village was then excluded during the
main data collection. Based on the experiences and
results of the pre-test, further re-training and refining of
techniques of interviewing and modification of research
tool was done. The research assistants used drug charts
containing samples of commonly used anti-malarial
medicines to aid recall and validate reports, remaining
packages or tablets were reviewed where possible. Hos-
pital cards were also reviewed to determine the duration
of treatment. Data was collected by the researcher and
field assistants. Qualitative data was also collected
through KIIs with healthcare providers and chemist shop
owners. Written informed consent was provided by the
study participants or, where participants were children, a
parent or guardian.
Statistical analyses
Statistical analyses were performed using Statistical
Packages for Social Sciences (SPSS, ver. 15.0). Descrip-
tive analysis was then conducted to determine adherence
level to ACT with reference to duration of treatment
and number of tablets taken in relation to the age of the
patient as recommended by the Ministry of Public
Health and Sanitation and Ministry of Medical Services
in Kenya (Table 1). In addition, a multivariate logistic re-
gression analyses between the independent and depend-
ant variables, was used to identify variables associated
with adherence to ACT. The independent variables in
the regression model included the following factors;
demographic (age, gender, marital status, household
head, and household size); socio-economic (source of in-
come, household monthly income, education level and
ability to read) and environmental (source of drugs, dis-
tance to source of drugs, and availability of anti-malarial
drug at source). Chi-square analyses were used to deter-
mine proportionality. Statistical significance was assessed
Table 1 Dosing schedule for Artemether-Lumefantrine (Coartem)
Weight
(Kg)
Age in years Number of tablets per dose
Day 1 Day 2 Day 3
1st dose 8 hours 24 hours 36 hours 48 hours 60 hours
5-14 5 months≤ 3 years 1 1 1 1 1 1
15-24 3-7 years 2 2 2 2 2 2
25-34 8-11 years 3 3 3 3 3 3
Above 34 ≥ 12 years 4 4 4 4 4 4
Source: [13] National Guidelines for the Diagnosis, Treatment and Prevention of Malaria in Kenya.
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at P ≤0.050. Data collected by KIIs was organized into
themes and analyzed.
Results
Demographic and socio-economic characteristics of the
study participants
Table 2 presents the demographic and socio-economic
characteristics of the study participants. A total of 388
households sampled were included in the analyses. Out of
388 households, 297 (76.5%) used ACT (Coartem/Arte-
mether Lumefantrine) while 91 (23.5%) used other anti-
malarial drugs. Overall, males were 186 (47.9%) while
females were 202 (52.1%). A total of 162 (41.8%) were
aged <13 years while 226 (58.90%) were ≥13 years. Ma-
jority of households consisted of 3–5 individuals [200
(52.5%)], others were >6 individuals [155 (40.0%)] and 1–
2 individuals [33(8.5%)]. Households headed by husbands
were 269 (69.3%) and wives, 119 (30.7%). Respondents
who were married comprised of 105 (27.1%), single 79
(20.4%), widowed 30 (7.7%), while underage (<15 years
and assumed to have not acquired marriageable age) were
169 (43.9%) (Table 1).
Amongst the parents/caretakers, 40 (10.3%) did not
have any formal education, 188 (48.5%) had primary edu-
cation, 116 (29.9%) had secondary education, 37 (9.5%)
had post-secondary education, while 7 (1.8%) were still in
school. A higher proportion of the respondents (68.3%)
were able to read, while 31.7% were unable to read the
written prescription (Table 2). Farming (38.9%) was the
main source of income; others were petty business
(20.6%), salaried employment (11.9%), casual work
(11.3%), and self-employment (17.3%). The respondents
with monthly income of below KShs. 4,500 (~ $56) were
204 (52.6%), between KShs. 4,500-9,000 ($56-112) were
133 (34.3%), while those with over KShs. 9,000 (>$ 112)
were 55 (13.1%) (Table 2).
Sources of anti-malarial drugs in the rural population
Results on the sources of anti-malarial drugs in Southeast
Alego location demonstrated that a total of 77.8% of all
anti-malarial drugs were from government institutions,
17.8% from nearby shops/pharmacies/chemists, 3.1%
given by neighbor/ friend/ relative, and 1.3% were left-
over drugs in the house (previously given in the hospital).
Out of those who used ACT (Coartem; n = 297), 278/
297 (93.6%) obtained the drugs from government insti-
tutions, 14/297 (4.7%) were given the drugs by friend/
neighbor/relative, 3/297 (1.0%) bought them from phar-
macy/shop and 2/297 (0.7%) used left-over medicine in
the house. Since the study mainly focused on ACT, dis-
tance to the source of ACT was measured based on the
time taken to reach ACT source while walking. The
respondents who used <30 minutes were 44.8% while
55.2% used >30 minutes.
Table 2 Demographic and socio-economic characteristics of the study population
Study participants n = 388
Used ACT 297 (76.5 %)
Did not use ACT 91(23.5 %)
Demographic Characteristics Number (%) Socio-economic Characteristics Number (%)
Age <13 years 162 (41.8 %) Education level None 40 (10.3 %)
≥13 years 226 (58.2 %) Primary 188 (48.5 %)
Gender Male 186 (47.9 %) Still in school 7 (1.8 %)
Female 202 (52.1 %) Secondary 116 (29.9 %)
Marital status Married 105 (27.1 %) Post-Secondary 37 (9.5 %)
Widowed 30 (7.7 %) Ability to read Able to read 265 (68.3 %)
Separated 5 (0.9 %) Unable to read 123 (31.7 %)
Single 79 (20.4 %) HHSI Salaried employment 47 (11.9 %)
Underage 169 (43.9 %) Self-employed 67 (17.3 %)
HH head Wife 119 (30.7 %) Petty business 80 (20.6)
Husband 269 (69.3 %) Casual work 44 (11.3 %)
HH size 1-2 33 (8.5 %) Farming 151 (38.9 %)
3-5 200 (52.5 %) HHMI <KShs.4,500 204 (52.6 %)
≥6 155 (40.0 %) KShs.4,500-9,000 133 (34.3 %)
Over KShs. 9,000 55 (13.1 %)
Legend: ACT- Artemisinin-based combined therapies, HHSI- Household source of income, HHMI- Household monthly income. From these results, majority of the
respondents were ≥13 years (58.2 %), female (52.1 %) and most HH had 3–5 occupants. The respondents with primary education were 48.5 %, majority were able
to read (68.3 %) written prescription, farming is the main HHSI and most HH have a monthly income of< KShs. 4,500 (52.6 %). KShs. 80 ~ 1$.
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ACT adherence level in a rural population of
western Kenya
In the context of the current study, adherence was
defined as abiding by the recommended dose and period
of usage of ACT. In order to assess level of adherence to
ACT use, the number of tablets taken in relation to age
and days of treatment were evaluated. Results revealed
that most of the respondents who took ACT [215/297
(~72.0%)] had the recommended number of tablets
according to their ages while others [82/297 (~28.0%)] ei-
ther took less or more than the recommended number.
Duration of treatment was also assessed and results
demonstrate that 161 (54.0%) took ACT within the
recommended 3 days, 22 (8.0%) within <3 days while 114
(38.0%) within >3 days. When combined (duration of
treatment and number of tablets taken), adherence level
was found to be 140 (47.0%) for adhered and 157 (53.0%)
for non-adherence.
Further analysis on adherence was conducted to deter-
mine the level of adherence with reference to demo-
graphic and socio-economic factors of the study
population. General stratification of adherence to ACT
and demographic factors revealed the following patterns:
57.9% of individuals <13 years and 42.1% of those
>13 years of age adhered. Additional stratification of
demographic factors [gender, marital status, household
(HH) head, and HH size] and adherence was also con-
ducted. Chi-square analyses revealed that age significantly
differed between the ACT adherents and non-adherents
(P= 0.011). However, gender, marital status, HH head,
and HH size were comparable between the ACT adher-
ents and non-adherents (P= 0.178, P= 0.220, P= 0.140,
and P= 0.121, respectively) (Table 3).
In order to determine adherence level with reference
to socio-economic factors, the study participants were
stratified according to education level, ability to read, in-
come per month and occupation. Chi-square analyses
demonstrated that education level (P< 0.01), monthly
income (P= 0.002) and ability to read (P< 0.01) signifi-
cantly differed between adherents and non-adherents
(Table 3). However, HH income source was compar-
able between the ACT adherents and non-adherents
(P= 0.094) (Table 4).
Factors associated with ACT adherence
In order to determine factors associated with adherence
to ACT in Southeast Alego location, multivariate logistic
regression analyses were performed. The independent
variables included demographic (age, gender, marital sta-
tus, household head, and household size), socio-economic
(household source of income, household monthly income,
education level and ability to read) and environmental
factors (source of drugs, distance to source of drugs, and
availability at source). The above factors were regressed
against the outcome variable; adherence. The full regres-
sion model of the demographic factors revealed that age
was a significant factor in determining ACT adherence
since many respondents (57.9%) who were <13 years
(OR, 0.571; 95%CI 0.306-0.905; P= 0.017) adhered as
opposed to respondents who were ≥13 years (42.1%)
(Table 3). Consistently, logistic regression model demon-
strated that low age (OR, 0.571, 95% CI, 0.360-0.905;
P= 0.017), higher education level (OR, 0.074; 95% CI
0.017-0.322; P< 0.01), ability to read (OR, 0.285, 95% CI,
0.167-0.486; P< 0.01) and higher income (Ksh.> 9000;
OR, 0.340; 95% CI, 0.167-0.694; P= 0.003) were associated
Table 3 Demographic factors associated with ACT adherence in Southeast Alego location
Demographic factors Adhered Did not adhere P-value a OR 95 % CI P-valueb
Age <13 years 81 (57.9 %) 69 (43.9 %) 0.011 0.571 0.360-0.905 0.017
≥13 years 59 (42.1 %) 88 (56.1 %) 1.00 (reference category)
Gender Male 62 (44.3 %) 79 (50.3 %) 0.178 1.274 0.807-2.013 0.229
Female 78 (55.7 %) 78 (49.7 %) 1.00 (reference category)
Marital status Married 30 (21.4 %) 42 (26.1 %) 0.220 1.540 0.872-2.720 0.137
Widowed 11 (7.9 %) 11 (7.0 %) 1.352 0.551-3.319 0.510
Separated 1 (0.7 %) 3 (1.9 %) 3.380 0.344-33.234 0.296
Single 18 (2.9 %) 31 (19.7 %) 1.779 0.922-3.434 0.086
Underage 80 (57.1 %) 71 (45.2 %) 1.00 (reference category)
HH head Wife 34 (24.3 %) 48 (30.6 %) 0.140 1.373 0.821-2.296 0.227
Husband 106 (75.7 %) 109 (69.4 %) 1.00 (reference category)
HH size 1-2 5 (3.6 %) 10 (6.4 %) 0.121 2.339 0.757-7.229 0.140
3-5 66 (47.1 %) 88 (56.1 %) 1.559 0.975-2.500 0.065
≥6 69 (49.3 %) 58 (36.9 %) 1.00 (reference category)
Legend: HH- Household, ACT- Artemisinin-based combined therapies. From the results, age significantly affected adherence in the study population (P= 0.011).
aStatistical significance determined by Chi-square tests. P-value is significant at P≤ 0.050. bStatistical significance determined by logistic regression tests.
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with ACT adherence (Tables 3–5). However, adherence
was not significantly associated with gender, HH size, HH
head, marital status, source of ACT and distance to the
source (Tables 3–5).
Accessibility of ACT
Accessibility was assessed by distance to drug source,
drug availability at the source, affordability and accept-
ability of ACT. Assessment of distance from the drug
source revealed that majority of the respondents cover
longer distances (55.2%) to reach the source of ACT.
Moreover, 52.9% of the respondents reported that ACT
was not always available at the source. Further analyses
revealed that drug availability (P= 0.020) and distance to
drug source (P< 0.01) significantly varied in the sub-
locations (Table 6).
In order to determine affordability, Key Informants
were asked about the cost of malaria treatment at the
health facilities. The respondents were also asked to
comment on ACT treatment. The results revealed that
ACT was more affordable at government health institu-
tions as compared to other sources. In these facilities,
with an average amount of KShs. 40, the respondents
could get ACT and analgesics. “What complicates this is
the distance to these health facilities”, noted one of the
key informants. At the dispensing chemist, ACT was
Table 4 Socio-economic characteristics and factors associated with adherence to ACT in Southeast Alego location
Socio-economic factors Adhered Did not adhere P-value a OR 95 % CI P-value b
Education level Primary 70 (50.0 %) 73 (46.5 %) 0.074 0.017-0.322 <0.01
Secondary 47 (33.6 %) 42 (26.8 %) 0.059 0.013-0.264 <0.01
Post-Secondary 17 (12.1 %) 11 (7.0 %) <0.01 0.038 0.008-0.195 >0.01
Still in school 4 (2.9 %) 2 (1.3 %)
None 2 (1.4 %) 29 (18.5 %) 1.00 (reference category)
HH inc. source Salaried employment 23 (16.4 %) 16 (10.2 %) 0.370 0.175-0.782 0.009
Self employed 28 (20.0 %) 21 (13.4 %) 0.444 0.224-0.878 0.020
Petty business 29 (20.7 %) 31 (19.7 %) 0.094 0.632 0.335-1.192 0.157
Casual worker 17 (12.1 %) 19 (12.1 %) 0.661 0.310-1.410 0.284
Farming 43 (30.7 %) 70 (44.6 %) 1.00 (reference category)
HH monthly inc. Below Ksh.4,500 60 (42.9 %) 99 (53.5 %) 1.00 (reference category)
Ksh.4500-9,000 55 (39.3 %) 42 (26.8 %) 0.002 0.451 0.269-0.754 0.002
Over Ksh. 9,000 25 (17.9 %) 16 (10.2 %) 0.340 0.167-0.694 0.003
Ability to read Able to read 114 (81.4 %) 90 (57.3 %) 0.285 0.167-0.486 <0.01
Unable to read 24 (18.6 %) 67 (42.7 %) <0.01 1.00 (reference category)
Legend: HH-Household, ACT- Artemisinin-based combined therapies, inc.-Income. From the results above, education level, household monthly income and ability
to read affected the proportions of those that adhered to ACT. The P-values in bold are statistically significant at P≤ 0.050. aStatistical significance determined by
Chi-square tests. bStatistical significance determined by logistic regression tests.
Table 5 Environmental factors associated with adherence to ACT in Southeast Alego location
Independent variables Adhered Did not adhere P-valuea OR 95 % CI P-valueb
Environmental factors
Source of ACT
Health facility 132 (95.7 %) 144 (91.7 %) 0.162 1.00 (reference category)
Bought drugs from Chemist 2 (1.4 %) 1 (0.6 %) 0.458 0.041-5.114 0.526
Left-over, given by neighbour /friend /relative 4 (2.9 %) 12 (7.6 %) 2.750 0.866-8.737 0.086
Availability at source
No 60 (42.9 %) 97 (61.8 %) 0.001 1.00 (reference category)
Yes 80 (57.1 %) 60 (38.2 %) 0.464 0.292-0.738 0.001
Distance to source
≤ 30 minutes 67 (47.9 %) 66 (42.0 %) 0.350 1.00 (reference category)
> 30 minutes 73 (52.1 %) 91 (58.0 %) 1.265 0.800-2.002 0.314
Legend: HH- Household; ACT- Artemisinin-based Combination Therapy. The results above show that availability of ACT at the source was significantly associated
with adherence to the drug and it was not associated to the source and distance to source of ACT. P-value in bold is statistically significant at P≤ 0.050. aStatistical
significance determined by Chi-square tests. bStatistical significance determined by logistic regression tests.
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sold at KShs. 250 and KShs. 450 (for child and adult
dose, respectively). In addition, the dispensing chemist
operators reported that as a result of the high costs, they
do not stock a lot of ACT, since they end up expiring on
the shelves. However, there were ACT (generics) which
retail at KShs. 40 in one chemist, and these were afford-
able to a majority of the study population.
In addition, acceptability level to ACT in treatment of
malaria was also examined with reference to the respon-
dents’ perception on its usage. The results revealed that
acceptability was high (95.4%) since only 4.4% of those
who used ACT were not content with it. Others com-
plained of the number of tablets taken (28.7%), duration
of treatment (9.5%) and the smell, taste and color
(29.1%) to be discouraging, however, they said that when
taken, it cures malaria (Table 7).
Discussion
It is of great importance to understand malaria treat-
ment through the use of ACT and its adherence with
the main aim of improving the usage patterns of this
valuable drug. Adherence to drug prescription is a key
factor in determining drug efficacy and effectiveness.
Non-adherence to prescription can translate to resist-
ance by the disease causative agent [21]. The current
study was designed to investigate adherence level, factors
that influence adherence and accessibility to ACT in
western Kenya. The findings from this study demon-
strated that non-adherence level was high (53%) in this
region. The results further revealed that most people
took more or less than 3 days to complete their ACT
treatment. In addition, individuals did not take the
recommended number of tablets even if they took them
within the recommended duration. This observation is
consistent with findings of other studies in Cambodia
and Maheba in Zambia in which high non-adherence to
ACT, SP and artesunate were reported [21,22].
Age, education level, household monthly income and
ability to read significantly varied between the adherent
and non-adherent respondents. Individuals with formal
education who were able to read the prescriptions were
likely to adhere to ACT. In addition, majority of those
earning moderate household monthly income, which in
essence translate to ability to purchase the ACT at the
recommended dosage also were adherent. These obser-
vations were supported by regression analyses that iden-
tified age, education level, ability to read, household
source of income, household monthly income and avail-
ability of drug (ACT) at source to be significantly asso-
ciated with ACT adherence. On the household source of
income, it was demonstrated that families which had sal-
aries and who were self employed adhered more com-
pared to those that relied on farming. This could be
attributed to the fact that, the salaried respondents had
some level of formal education and could therefore read
the prescriptions. Economically, farming in this area was
less productive and this could also limit the ability of the
households to purchase ACT if unavailable from the
Table 6 ACT availability and distance to source per sub-location
Availability at source Distance to source
Sub-location Yes No P-value ≤ 30 minutes >30 minutes P-value
Masumbi 45 (55.6 %) 36 (44.4 %) 27 (33.3 %) 81 (66.7 %)
Nyang’oma Kogelo 17 (31.5 %) 37 (68.5 %) 34 (63.0 %) 20 (37.0 %)
Mur Ng’iya 31 (41.9 %) 43 (58.1 %) 0.020 26 (35.1 %) 48 (64.9 %) 0.001
Bar Agulu 47 (53.4 %) 41 (46.6 %) 46 (52.3 %) 42 (47.7 %)
Total 140 (47.1 %) 157 (52.9 %) 133 (44.8 %) 191 (55.2 %)
Legend: From the above results, distance to source and availability at source was significantly different across the sub-locations. aStatistical significance
determined by Chi-square tests. P-value is significant at P≤ 0.050.
Table 7 Respondents perception on ACT use in treatment of malaria
Perception Frequency Percentage (%)
ACT (Coartem) treats malaria 45 15.2
ACT (Coartem) do not treat malaria 13 4.4
People adhere to ACT (Coartem prescription) 29 9.8
Duration of treatment is too long hence non-adherence 28 9.5
ACT tablets are too many hence non-adherence 85 28.7
ACT (Coartem) has bad taste, smell and color 86 29.1
People do not adhere since when they start feeling better, they forget and discontinue treatment 10 3.4
Legend: Most of the respondents reported that ACT had bad taste, smell and color (29.1 %) and numbers of ACT tablets taken were too many (28.7 %) but it
cures malaria. Only 4.4 % were not content with the drug.
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government health facilities. The results presented here,
however, show that gender, household head, household
size and marital status did not influence adherence to
ACT prescription. Consistently, a previous study carried
out in Turkey to determine knowledge on malaria and
behaviour in an endemic rural area demonstrated no
relationships between adherence and race, gender, edu-
cational experience, household head and marital status
[23]. However, the results of the current study are incon-
sistent with a previous study in Sudan among college
students examining self-medication practices with anti-
biotics and anti-malarials. In this study, gender was
found to be a significant factor in determining anti-
malarial and antibiotic use. In the same study [24], as
well as another community-based cross-sectional survey
in the Tulu district in southern–central Ethiopia [25],
age was a significant factor in determining treatment-
seeking behaviour for malaria. The lack of influence of
gender, household head and marital status on adherence
to ACT could be attributed to the fact that once one ac-
quire malaria, the preceding conditions irrespective of
the listed status would call for immediate medication.
A further assessment of socio-economic factors that
could influence adherence revealed that household
monthly income, education level and ability to read influ-
enced adherence. This is because majority of households
with income of more than KShs. 9,000 ($112) per month
took correct dosages as opposed to those with income of
below KShs. 4,500 ($56) or between KShs. 4,500-9,000
($56-112). These results are comparable with a study in
Tanzania in which it was demonstrated that children from
relatively poorer households were less likely to be adher-
ent to prescription as compared to those from wealthier
families [26]. In the current study, it can as well be argued
that higher income households are able to afford buying
drugs when required. Consistently, a study in Maheba
refugee camp in Zambia, reported that the refugees were
leaving in precarious conditions and this affected their
socio-economic conditions possibly resulting to high
non-adherence [21].
Assessment of environmental factors that can influ-
ence drug adherence revealed that availability at source
influenced pattern of adherence. Availability of drugs
determines which drugs are obtainable for use at the
source. Majority of the respondents mainly relied on
government health institutions as source of these drugs.
This is because most of the respondents were relatively
poor and could not afford to buy these drugs at the re-
tail pharmacies or visit a private clinic. Government
health facilities are not reliable sources of the drug since
most of them suffer ‘a drug is out of stock syndrome’
and this could be a possible reason for non-adherence.
However, when given at these government health institu-
tions, they are given full dose unlike when they buy the
drugs independently. These findings are, however, incon-
sistent with those of a study carried out in southern
Ethiopia on self-treatment of malaria in rural communi-
ties, where anti-malarial drugs were bought from mar-
kets or any shops because it was close to home (43.6%),
the drugs were available (25.8%), the shops were easily
accessible (20.9%), and waiting time was short (11.5%)
[27]. Moreover, it is worth noting that distance to the
source of drugs in the current study did not influence
adherence in this study. Previous studies have shown
that household distance to health facilities is a critical
determining factor to adherence. For example, the study
in Maheba, Zambia established that the refugees while
fleeing from war and violence, were surviving on limited
resources for many years, and did not have regular ac-
cess to health care or education; hence, this affected
their adherence to ACT prescription [21].
Assessment of accessibility of ACT revealed that avail-
ability of the drug was low since ACT was not always
available at its source and majority covered longer dis-
tance to the source. These results are comparable to pre-
vious ones in Cambodia in which access to ACT in
remote areas was determined and shown to be low [28].
Another study conducted in Kenya to assess access to
anti-malarials revealed that majority of ill individuals, es-
pecially the poor, had no access to prompt effective treat-
ment [29]. Additional studies on policy in practice in
Kenya showed that health facilities suffered from chronic
drug shortages due to delays in drugs deliveries from the
central level and the failure to adjust drug quantities to
suit seasonal fluctuations in disease burden [30].
In addition, the current results revealed that ACT is
affordable at government health institutions. Patients
aged 5 years and below are treated free of charge and
those above 5 years are charged an average of KShs. 40,
after which they are issued with Artemesinin Lumefan-
trine (AL) and analgesics. Most respondents cannot pur-
chase the same drugs in pharmacy outlets since the
prices are KShs. 250 (~$4) as compared to the KShs. 40
($0.5) in government health institutions. The issue on
high costs could also explain the reason why most of the
respondents reported that when ACT is not available at
the health facility, they buy cheaper alternative anti-
malarials or just analgesics and wait until ACT are avail-
able. Other studies have also revealed that reduced
charges at health facilities can improve accessibility
[29,31,32].
Furthermore, ACT acceptability in treatment of mal-
aria was high in this study since only 4.4% of those who
used ACT said that they were not content with its usage.
Majority reported that ACT was effective in treatment
of malaria with a small proportion believing that it was
not effective. The results are consistent with those of
clinical trials on ACT in the treatment of multi-drug
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resistant and acute P. falciparum malaria, which demon-
strated favourable tolerability, high efficacy and adequate
parasitological response to ACT in general and in par-
ticular to the standard 6-dose regimen [33,34]. The
results of this study also revealed that there is inad-
equacy in the supply of ACT in the study area. Most of
the health institution in this area continually battle with
‘drug is out-of-stock syndrome’. In Kenya, adequacy of
supplies of these drugs is a challenge. Often, public
health facilities do not have the recommended anti-
malarials in stock. Lack of medicine in the government
health facilities contributes to people buying drugs over-
the-counter (OTC), where the quality of the drugs is not
controlled and information on dosage is not often pro-
vided [30].
Study limitations
The study was based on both self-reported and
medically-diagnosed episodes of malaria experienced in
the previous two weeks prior to the interview. Hence,
we could not verify the authenticity of the information
obtained from the respondents. Secondly, the case-
specific definition of malaria could not be ascertained in
this study, since some sought to over-the-counter drugs
when they had symptoms similar to those of malaria.
Moreover, there was recall bias in this report. Partici-
pants were asked questions based on a two-week recall
period. Some of the participants would therefore, not
vividly remember whether they actually had malaria/
fever or how they took the drugs in the last two weeks
preceding the interview. To increase accuracy on dur-
ation of treatment, hospital cards were reviewed and the
drug sachets observed and number of tablets remaining
or taken were counted. This certainly affected the quality
of this study. However, the two week recall period is the
reference period used by WHO surveys and has been
adopted by many researchers for similar surveys. There-
fore, findings in this report are of comparable quality.
Similarly, structured interview-based studies are limited
by the pre-determined responses, which are susceptible
to response bias. However, attempts were made to
minimize this potential source of bias by testing the tool,
training field assistants in its administration, and amend-
ing it to make the wording familiar and culturally-
appropriate. Finally, not asking study participants how
they took Co-Artem or what advice they were given
about how to take their Co-Artem was the other major
limitation of the study since we could not asses the level
of failure rates as a result of these components. This fol-
lows previous observations that absorption of hydropho-
bic lipophilic lumefantrine is greatly increased by a small
amount of fat (1.2 g) co-administration [35] and failure
to implement this component during prescribing result
in increased failure rates [36].
Conclusions
This study has shown that the key challenge in changing
malaria treatment policy to ACT is patients’ adherence to
drug prescription and ensuring adequate access to ACT
in poor rural settings where communities have limited
health care services. Adherence level was low in the study
area and there is potential need for interventions to im-
prove patient adherence. Patient-centered care will be
vital to encourage adherence to new treatment algorithms
developed in response to the changing malaria environ-
ment in Kenya. Behaviour-change-communication (BCC)
programmes should be initiated to aid in awareness cre-
ation on the consequence of non-adherence [37-39].
Monitoring patient adherence is thus quite necessary to
maintain ACT efficacy. There is also need for equitable
distribution of resources in the country to ensure that the
remote rural areas have access to quality formal education
and drugs since these significantly influence accessibility.
In addition, through Affordable Medicines Facility for
Malaria (AMFm) funded through Global Fund, it is
anticipated that people suffering from malaria will have
access to inexpensive and effective anti-malarial treat-
ment. Further studies should be considered on accessibil-
ity to ACT when the AMFm funds become available
since adherence to the drug regimen may be influenced
by several factors ranging from policy to demand and
supply. Future studies should mainly assess these policy
factors.
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